A5046290243- Renal cell carcinoma treatment
- Cancer Research and Treatments
- Cancer Genomics and Diagnostics
- Cancer Cells and Metastasis
- Tissue Engineering and Regenerative Medicine
- Multiple and Secondary Primary Cancers
- Hemostasis and retained surgical items
- Renal and related cancers
- Cancer Immunotherapy and Biomarkers
- Ferroptosis and cancer prognosis
Johns Hopkins Medicine
2025
Johns Hopkins University
2025
Sidney Kimmel Comprehensive Cancer Center
2024
Metastatic translocation renal cell carcinomas (mtRCCs) are rare and aggressive tumors with limited treatment options. Recent studies demonstrated promising activity of immune-oncology (IO) combinations in mtRCC. However, the effectiveness dual IO versus plus VEGF-TKI remains unclear. We conducted a retrospective analysis mtRCC patients at 4 institutions. Eligible had confirmed by genitourinary pathologist received combination therapy (IO+IO or IO+VEGF-TKI). Clinical data outcomes were...
4512 Background: Chromophobe renal cell carcinoma (ChRCC) represents ~5-10% of all RCCs. Given its rarity, there is limited clinical trial data to guide systemic therapy for metastatic disease. Phase 2 trials have demonstrated that targeted agents inhibiting vascular endothelial growth factor receptor and mammalian target rapamycin similar efficacy in ChRCC compared conventional RCC. However, immune checkpoint inhibitor (IO) containing regimens appear less efficacious other RCC subtypes....
446 Background: Numerous combos of ICIs and Tyrosine Kinase Inhibitors (TKIs) have received approval for the management mccRCC. Specific peripheral blood cell counts reflect inflammation impact anti-tumor immunity, here we investigated their role as biomarkers clinical benefit to ICI in RCC. Methods: We performed a retrospective study 179 mccRCC patients treated with ≥ 4 weeks (2013-2023), where examined baseline 6-week post-treatment Neutrophil Lymphocyte ratio (NLR), Red Distribution Width...